ABBV•benzinga•
Bristol Myers' Cobenfy Falls Short On Primary Endpoint In Phase 3 Schizophrenia Trial, Stock Slides
Summary
Bristol Myers' Cobenfy missed its primary endpoint in the Phase 3 ARISE trial but showed symptom improvement in certain subgroups.
Original Article
Read the full article from the original source for complete details and context.
Read Full ArticleArticle published on April 23, 2025 by benzinga